FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075352627> ?p ?o ?g. }

• W2075352627 endingPage "1373" @default.
• W2075352627 startingPage "1354" @default.
• W2075352627 abstract "As the only oral anticoagulation option available in the United States, warfarin use remains widespread. However, concerns of safety remain a substantial issue. Additional anticoagulation options include unfractionated heparin, low-molecular-weight heparins (e.g., enoxaparin, dalteparin, and tinzaparin), and the indirect-acting factor Xa inhibitor, fondaparinux. Direct thrombin inhibitors represent a newer class of anticoagulants used primarily in the treatment of heparin-induced thrombocytopenia and percutaneous coronary interventions. Three intravenous agents are currently available—lepirudin, bivalirudin, and argatroban—with an oral agent, dabigatran etexilate, undergoing clinical investigation. Dabigatran etexilate offers a rapid onset of action after oral administration, reaching peak plasma concentrations and onset of anticoagulant effect within 0.5–2 hours after administration. Studies have demonstrated linear pharmacokinetics, a linear relationship between ecarin clotting time and international normalized ratio, and no known clinically significant drug or food interactions. Dabigatran etexilate has been studied in clinical trials as prophylaxis for venous thromboembolism in patients undergoing total knee replacement or total hip replacement surgeries, as well as for stroke prevention in patients with atrial fibrillation. Dabigatran etexilate has demonstrated superiority and noninferiority to enoxaparin as prophylaxis for venous thromboembolism in patients undergoing orthopedic surgery, with the most frequent adverse effects being gastrointestinal complaints. Elevations in alanine aminotransferase concentrations were noted in small percentages of patients in both the dabigatran etexilate and enoxaparin groups, with no observed dose association. The overall rates of major bleeding were low, with minor bleeding commonly noted, often at surgical sites. Clinical trials of dabigatran etexilate in patients with atrial fibrillation are ongoing. Results of short-term efficacy and safety appear promising. Further research is needed regarding long-term safety and efficacy for other anticoagulation indications." @default.
• W2075352627 created "2016-06-24" @default.
• W2075352627 creator A5003309680 @default.
• W2075352627 creator A5076594754 @default.
• W2075352627 date "2008-11-01" @default.
• W2075352627 modified "2023-09-24" @default.
• W2075352627 title "Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases" @default.
• W2075352627 cites W1531871815 @default.
• W2075352627 cites W161992551 @default.
• W2075352627 cites W1738640266 @default.
• W2075352627 cites W1827341053 @default.
• W2075352627 cites W1966218617 @default.
• W2075352627 cites W1967889750 @default.
• W2075352627 cites W1970558449 @default.
• W2075352627 cites W1973233314 @default.
• W2075352627 cites W1978051825 @default.
• W2075352627 cites W1995144193 @default.
• W2075352627 cites W2000438765 @default.
• W2075352627 cites W2006931225 @default.
• W2075352627 cites W2012761317 @default.
• W2075352627 cites W2019561783 @default.
• W2075352627 cites W2031581415 @default.
• W2075352627 cites W2035193897 @default.
• W2075352627 cites W2039556534 @default.
• W2075352627 cites W2045913143 @default.
• W2075352627 cites W2046051565 @default.
• W2075352627 cites W2052443929 @default.
• W2075352627 cites W2054740753 @default.
• W2075352627 cites W2059732032 @default.
• W2075352627 cites W2063916070 @default.
• W2075352627 cites W2066009006 @default.
• W2075352627 cites W2068476516 @default.
• W2075352627 cites W2082739034 @default.
• W2075352627 cites W2096698984 @default.
• W2075352627 cites W2098108939 @default.
• W2075352627 cites W2104486401 @default.
• W2075352627 cites W2115348966 @default.
• W2075352627 cites W2117616041 @default.
• W2075352627 cites W2124882231 @default.
• W2075352627 cites W2127441164 @default.
• W2075352627 cites W2134355273 @default.
• W2075352627 cites W2134908914 @default.
• W2075352627 cites W2150567120 @default.
• W2075352627 cites W2155795805 @default.
• W2075352627 cites W2156611099 @default.
• W2075352627 cites W2157065952 @default.
• W2075352627 cites W2160263071 @default.
• W2075352627 cites W2165506983 @default.
• W2075352627 cites W2590468594 @default.
• W2075352627 cites W4297754350 @default.
• W2075352627 doi "https://doi.org/10.1592/phco.28.11.1354" @default.
• W2075352627 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18956996" @default.
• W2075352627 hasPublicationYear "2008" @default.
• W2075352627 type Work @default.
• W2075352627 sameAs 2075352627 @default.
• W2075352627 citedByCount "97" @default.
• W2075352627 countsByYear W20753526272012 @default.
• W2075352627 countsByYear W20753526272013 @default.
• W2075352627 countsByYear W20753526272014 @default.
• W2075352627 countsByYear W20753526272015 @default.
• W2075352627 countsByYear W20753526272016 @default.
• W2075352627 countsByYear W20753526272017 @default.
• W2075352627 countsByYear W20753526272018 @default.
• W2075352627 countsByYear W20753526272019 @default.
• W2075352627 countsByYear W20753526272021 @default.
• W2075352627 countsByYear W20753526272022 @default.
• W2075352627 countsByYear W20753526272023 @default.
• W2075352627 crossrefType "journal-article" @default.
• W2075352627 hasAuthorship W2075352627A5003309680 @default.
• W2075352627 hasAuthorship W2075352627A5076594754 @default.
• W2075352627 hasConcept C126322002 @default.
• W2075352627 hasConcept C141071460 @default.
• W2075352627 hasConcept C2776301958 @default.
• W2075352627 hasConcept C2776710957 @default.
• W2075352627 hasConcept C2776877702 @default.
• W2075352627 hasConcept C2777292125 @default.
• W2075352627 hasConcept C2777565915 @default.
• W2075352627 hasConcept C2777987278 @default.
• W2075352627 hasConcept C2778205648 @default.
• W2075352627 hasConcept C2778661090 @default.
• W2075352627 hasConcept C2778810321 @default.
• W2075352627 hasConcept C2779161974 @default.
• W2075352627 hasConcept C2779612170 @default.
• W2075352627 hasConcept C2779630707 @default.
• W2075352627 hasConcept C2780205058 @default.
• W2075352627 hasConcept C2780400711 @default.
• W2075352627 hasConcept C2780868729 @default.
• W2075352627 hasConcept C2991741193 @default.
• W2075352627 hasConcept C42219234 @default.
• W2075352627 hasConcept C500558357 @default.
• W2075352627 hasConcept C57002609 @default.
• W2075352627 hasConcept C71924100 @default.
• W2075352627 hasConcept C89560881 @default.
• W2075352627 hasConceptScore W2075352627C126322002 @default.
• W2075352627 hasConceptScore W2075352627C141071460 @default.
• W2075352627 hasConceptScore W2075352627C2776301958 @default.
• W2075352627 hasConceptScore W2075352627C2776710957 @default.
• W2075352627 hasConceptScore W2075352627C2776877702 @default.

• next